Patents Represented by Attorney Patricia Anne Perkins

Find this attorney in the Justia Lawyer Directory

  • Type II Interleukin-1 receptors
    Patent number: 5464937
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: November 7, 1995
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Purification of fusion proteins comprising GM-CSF and IL-3
    Patent number: 5463029
    Abstract: A process for purifying a fusion protein comprising GM-CSF and IL-3 is disclosed.
    Type: Grant
    Filed: November 23, 1992
    Date of Patent: October 31, 1995
    Assignee: Immunex Corporation
    Inventors: Joseph T. Dunn, Stephen M. Waugh
  • Cytokine which is a ligand for OX40
    Patent number: 5457035
    Abstract: There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: October 10, 1995
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, William C. Fanslow, III, Richard B. Gayle, Raymond G. Goodwin
  • DNA sequences encoding granulocyte-colony stimulating factor receptors
    Patent number: 5422248
    Abstract: Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: June 6, 1995
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Alf D. Larsen, John E. Sims, Benson M. Curtis
  • Peptide for detecting antibodies to a 260 kD T. cruzi antigen
    Patent number: 5413912
    Abstract: There is disclosed an antigenic peptide that comprises at least 15 amino acids having the sequence Ala Glu Pro Lys X Ala Glu Pro Lys X Ala Glu Pro Lys X, wherein X is Pro or Ser. This peptide is useful in an ELISA assay to detect antibodies specific to T. cruzi infection and Chagas disease. This peptide is further useful in a vaccine composition for immunizing an individual to prevent Chagas disease upon exposure to T. cruzi.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: May 9, 1995
    Inventor: Steven G. Reed
  • Method of detecting anti-leishmania parasite antibodies
    Patent number: 5411865
    Abstract: A method for detecting anti-Leishmania parasite antibodies to a 230 kDa antigen present in Leishmania chagasi and Leishmania donovani is disclosed which comprises obtaining a sample from an individual, contacting the sample with a recombinant K39 repeat unit antigen comprising the amino acid sequence as shown in SEQ ID NO:3, and detecting the presence of anti-Leishmania parasite antibodies in the sample which bind to the recombinant K39 repeat unit antigen.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: May 2, 1995
    Assignee: Iasys Corporation
    Inventor: Steven Reed
  • Fusion proteins comprising MGF and IL-3
    Patent number: 5376367
    Abstract: A fusion protein which comprises MGF and IL-3. Such fusion proteins have enhanced biological activity.
    Type: Grant
    Filed: November 22, 1991
    Date of Patent: December 27, 1994
    Assignee: Immunex Corporation
    Inventor: Douglas E. Williams
  • Isolated poxvirus A53R-equivalent tumor necrosis factor antagonists
    Patent number: 5359039
    Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to Tumor Necrosis Factor, thereby functioning as Tumor Necrosis Factor antagonists. Also disclosed are processes for preparing isolated viral protein cytokine antagonists.
    Type: Grant
    Filed: July 9, 1993
    Date of Patent: October 25, 1994
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • DNA encoding type II interleukin-1 receptors
    Patent number: 5350683
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: July 12, 1993
    Date of Patent: September 27, 1994
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • IgA Fc receptors
    Patent number: 5328987
    Abstract: The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: July 12, 1994
    Assignee: Immunex Corporation
    Inventor: Charles R. Maliszewski
  • Peptide for diagnosing and immunizing against T. cruzi infection
    Patent number: 5304371
    Abstract: There is disclosed an antigenic peptide that comprises at least 15 amino acids having the sequence Ala Glu Pro Lys X Ala Glu Pro Lys X Ala Glu Pro Lys X, wherein X is Pro or Ser. This peptide is useful in an ELISA assay to detect antibodies specific to T. cruzi infection and Chagas disease. This peptide is further useful in a vaccine composition for immunizing an individual to prevent Chagas disease upon exposure to T. cruzi.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: April 19, 1994
    Assignee: Lasys Corporation
    Inventor: Steven G. Reed
  • Hyperglycosylated cytokine conjugates
    Patent number: 5298395
    Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues. Methods of using such ligand reagents are also disclosed.
    Type: Grant
    Filed: November 5, 1992
    Date of Patent: March 29, 1994
    Assignee: Immunex Corporation
    Inventor: Linda S. Park
  • Adoptive immunotherapy with interleukin-7
    Patent number: 5229115
    Abstract: There is disclosed an immunotherapy method for treating an individual with cancer or a viral infection comprising obtaining lymphoid cells previously exposed to a specific antigen, culturing the lymphoid cells ex vivo in a culture medium containing an effective amount of an IL-7 polypeptide or a functional derivative thereof to induce CTL activity in the lymphoid cells and administering the lymphoid cells having CTL activity for cells displaying the specific antigen to an individual.
    Type: Grant
    Filed: July 26, 1990
    Date of Patent: July 20, 1993
    Assignee: Immunex Corporation
    Inventor: David H. Lynch
  • Interleukin-4 binding protein-.gamma.
    Patent number: 5223605
    Abstract: Isolated and purified Interleukin-4 Binding Protein-.gamma. (IL-4bp.gamma.) and methods for obtaining isolated and purified IL-4bp.gamma..
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: June 29, 1993
    Assignee: Immunex Corporation
    Inventors: William C. Fanslow, Richard J. Armitage
  • Hyperglycosylated cytokine conjugates
    Patent number: 5217881
    Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues.
    Type: Grant
    Filed: January 24, 1992
    Date of Patent: June 8, 1993
    Assignee: Immunex Corporation
    Inventor: Linda S. Park
  • DNA encoding IgA Fc receptors
    Patent number: 5198342
    Abstract: The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.
    Type: Grant
    Filed: July 5, 1990
    Date of Patent: March 30, 1993
    Assignee: Immunex Corporation
    Inventor: Charles R. Maliszewski
  • Nonglycosylated human interleukin-3 analog proteins
    Patent number: 5128450
    Abstract: The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro.sup.8 Asp.sup.15 Asp.sup.70) analog proteins expressed by transformed yeast of the species Saccharomyces cerevisiae, which when administered to a primate do not result in detectable urticaria.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: July 7, 1992
    Inventors: David L. Urdal, Helmut M. Sassenfeld